お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
985629

がん向け生物毒医薬品の世界市場:機会・治療薬の売上&臨床試に関する考察 (~2026年)

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 330 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.99円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

がん向け生物毒医薬品の世界市場:機会・治療薬の売上&臨床試に関する考察 (~2026年)
出版日: 2021年02月02日
発行: KuicK Research
ページ情報: 英文 330 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん向け生物毒医薬品は、持続可能な結果の達成および将来のがん治療情勢を変化させる広範なアプリケーションにより、市場の全体的な展望は前向きに見えます。

市場の主な促進要因として、がん症例数の増加、がん死亡率の増加、がんへの生物毒素の適用に関する意識の高まり、および市場で利用可能な他の治療法の高い失敗率などが挙げられます。

当レポートでは、世界のがん向け生物毒医薬品市場について調査分析し、市場の概要、がん管理における生物毒の役割、がんを標的とする生物毒の種類、がん向け生物毒市場の成長が他のがん治療薬に与える影響、各種がん向けの生物毒、研究動向、臨床パイプライン、および主要企業などについて分析しています。

目次

第1章 生物毒のイントロダクション

  • 概要
  • 強力な抗がん治療薬としての生物毒の進化

第2章 がん管理における生物毒の役割

第3章 がんを標的とする生物毒の種類

  • 一本鎖生物毒
  • 孔形成毒素
  • 炭疽菌毒素

第4章 がん向け生物毒市場の成長が他の実行可能ながん治療薬に与える影響

  • 世界におけるがん免疫療法市場に対するがん生物毒治療薬市場の影響
    • がん向け生物毒治療薬 vs. 免疫チェックポイント阻害剤療法
    • がん向け生物毒治療薬 vs. 免疫療法モノクローナル抗体
    • がん向け生物毒治療薬 vs. がんワクチン市場
  • 世界におけるがんの生物毒療法市場が過去の&伝統的ながん治療に及ぼす影響
    • がん向け生物毒治療薬 vs. がん患者向け化学療法
    • がん向け生物毒治療薬 vs. がん治療向け放射線療法
    • がん向け生物毒治療薬 vs. がん治療向け外科手術

第5章 脳腫瘍向け生物毒

  • 脳腫瘍の標的化に使用される毒素
  • 脳腫瘍に対する緑膿菌外毒素ベースの免疫毒素
    • IL4-PE
    • IL13-PE
    • TP-38
  • 脳腫瘍に対するジフテリア毒素ベースの免疫毒素
    • Tf-CRM107
    • DTAT&DTAT13
  • 脳腫瘍を標的とするための抗原
    • トランスフェリン受容体
    • インターロイキン-4受容体
    • インターロイキン-13受容体
    • 上皮成長因子受容体
    • その他の抗原

第6章 血液腫瘍に対する生物毒

  • 白血病およびリンパ腫における生物毒の役割
  • 進行中の研究開発

第7章 固形腫瘍の標的化に使用される生物毒

  • 固形腫瘍治療への影響
  • 進行中の研究&進歩

第8章 乳がん向け生物毒

  • 乳がんにおける生物毒の応用
  • 進行中の開発

第9章 肺がん向け生物毒

  • 役割&アプリケーション
  • 最近の研究開発

第10章 他のがん向けの生物毒

  • 前立腺がん
  • 黒色腫
  • 結腸直腸がん
  • 婦人科がん
  • 消化器がん

第11章 世界の免疫毒素市場:入手可能性、投与量、特許および価格分析

  • Lumoxiti(Moxetumomab pasudotox)

第12章 がん向け生物毒市場のための研究&医学的進歩

  • UCLAの研究者はDiazonaangulata (魚介類) 由来のタンパク質を使用してがんの副作用を最小限に抑える
  • 患者の胃がん細胞に対して有効なボツリヌス毒素
  • 食道がん治療後の合併症を劇的に軽減するボツリヌス毒素A
  • より良い結果を示す皮膚平滑筋腫に対するボツリヌス毒素A
  • 進行性固形がんの治療のためのTR1801-ADCの特性評価
  • 化学療法と放射線療法の有効性を高めるボツリヌス毒素
  • ボツリヌス毒素Aは乳がん手術後の持続性の痛みを治療
  • 新たに発見されたボツリヌス毒素Xは、がんやその他の病気の治療に役立つ可能性

第13章 がん向け生物毒:臨床試験の洞察

  • フェーズ別
  • ステータス別
  • がん種類別
  • 国別

第14章 世界におけるがん向け生物毒の臨床パイプライン:企業・適応症・フェーズ別

  • 研究
  • 前臨床
  • フェーズI
  • フェーズI / II
  • フェーズII
  • フェーズII / III
  • フェーズIII
  • 事前登録
  • 登録済み

第15章 市販のがん向け生物毒の臨床的洞察:Moxetumomab Pasudotox(Lumoxiti)

第16章 世界のがん向け生物毒治療薬市場力学

  • 有利な市場パラメータ
  • 市場の課題

第17章 がん向け生物毒市場の将来の方向性

第18章 競合情勢

  • Angimmune
  • Eisai
  • Molecular Template (mTEM)
  • Astrazeneca
  • Research Corporation Technologies
  • Sanofi
  • Seattle Genetics
  • Roche
  • Neopharma
  • Xenova Biomedix
図表

List of Figures

  • Figure 1-1: Evolution of Biological Toxins as Anticancer Therapeutics
  • Figure 2-1: Management of Biological Toxins in Cancer Treatment
  • Figure 3-1: Components of Immunotoxins
  • Figure 3-2: Components of Targeted Toxins
  • Figure 3-3: Types of Cancer Targeting Biological Toxins
  • Figure 3-4: Structure of Diphtheria Toxin & Denileukin diftitox (Ontak)
  • Figure 3-5: Mechanism of Denileukin diftitox (Ontak)
  • Figure 3-6: Mechanism of Pore Forming Biological Toxins
  • Figure 4-1: Cancer Biological Toxins Vs. Monoclonal Antibody
  • Figure 4-2: Old & Traditional Cancer Therapies Available in Therapeutics Market
  • Figure 4-3: Cancer Biological Toxin Therapy Action Vs. Chemotherapy Drug Action
  • Figure 4-4: Cancer Biological Toxin Vs. Surgical Removal of Cancer Cells
  • Figure 5-1: Commonly used Biological Toxins for Targeting Brain Tumor
  • Figure 5-2: Pseudomonas Exotoxin Based Immunotoxins
  • Figure 5-3: Diphtheria Toxin Based Immunotoxins under Development Phase
  • Figure 5-4: Antigens/ Receptors for Targeting Brain Tumor
  • Figure 5-5: Cintredekin Besudotox - Orphan Drug Designation Year by Indication
  • Figure 5-6: D2C7-IT Trial - Trial Initiation & Expected Completion Year
  • Figure 5-7: Role of Urokinase-Type Plasminogen Activator Receptor in Brain Tumor
  • Figure 6-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-3: Commonly used Biological Toxins for Targeting Haematological Tumor
  • Figure 6-4: Target Receptor for Ontak
  • Figure 6-5: Resimmune - FDA Orphan Designation & Fast Track Designation Year
  • Figure 6-6: Immunotoxin Receptors for Haematological Cancer
  • Figure 6-7: Investigational Immunotoxins for Haematological Cancer
  • Figure 6-8: Mechanism of LMB2 against Cells of Hematological Tumors
  • Figure 6-9: LMB-2 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 6-10: LMB-2 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-11: BL22 (CAT-3888) - Mechanism of Action against Hematological Malignancy
  • Figure 6-12: DT388GMCSF: Mechanism of Action Against Leukemia Cells
  • Figure 6-13: Resimmune - Mechanism of Action Against Cutaneous T Cell Lymphoma
  • Figure 6-14: Mechanism of MT-3724 in Hematological Cancer
  • Figure 6-15: MT-3724 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-16: MT-3724 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 7-1: Biological Toxins for Targeting Solid Tumors
  • Figure 7-2: Limitations of Immunotoxins in Solid Tumors
  • Figure 7-3: Immunotoxin for Solid Tumors by Target Receptor
  • Figure 7-4: Investigational Immunotoxins for Solid Tumor
  • Figure 7-5: SS1P - Mechanism of Action against Solid Tumor
  • Figure 7-6: LMB-100 - Mechanism of Action against Solid Tumors
  • Figure 7-7: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 7-8: LMB-100 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 7-9: LMB-7 - Mechanism of Action against Solid Tumors
  • Figure 8-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 8-2: Biological Toxins Used for Targeting Breast Cancer
  • Figure 8-3: Approaches Used to Overcome Immunogenicity
  • Figure 8-4: Investigational Immunotoxins for Breast Cancer
  • Figure 9-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
  • Figure 9-2: Biological Toxins used for Targeting Lung Cancer
  • Figure 9-3: Antigens/Receptors Expressed Over Lung Cancer Cells
  • Figure 9-4: Investigational Immunotoxins for Lung Cancer
  • Figure 10-1: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
  • Figure 10-2: Commonly used Biological Toxins for Targeting Prostate Cancer
  • Figure 10-3: Role of A-dmDT390-ScfbDb(PSMA) in Prostate Cancer
  • Figure 10-4: Investigational Immunotoxins for Prostate Cancer
  • Figure 10-5: Global - Newly Diagnosed Cases & Deaths related to Melanoma, 2020
  • Figure 10-6: Mechanism of PE Based Immunotoxins against Melanoma Cells
  • Figure 10-7: Antigens/Receptors Expressed Over Melanoma Cells
  • Figure 10-8: Mechanism of 9.2.27PE
  • Figure 10-9: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
  • Figure 10-10: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
  • Figure 10-11: Antigens/Receptors Expressed Over Cells of Colorectal Cancer
  • Figure 10-12: Investigational Immunotoxins for Colorectal Cancer
  • Figure 10-13: BM7PE Trial - Study Initiation & Expected Completion Year
  • Figure 10-14: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
  • Figure 10-15: Global - Number of Deaths by Leading Gynecological Cancer, 2020
  • Figure 10-16: Antigens/Receptors Expressed Over Cells of Gynecological Cancers
  • Figure 10-17: Investigational Immunotoxins for Gynecological Cancer
  • Figure 10-18: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
  • Figure 10-19: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
  • Figure 10-20: Antigens/Receptors Expressed Over Cells of Gastrointestinal Cancers
  • Figure 10-21: Investigational Immunotoxins for Gastrointestinal Cancer
  • Figure 10-22: LMB-100 Phase Ib/II Trial - Study Initiation & Expected Completion Year
  • Figure 10-23: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 11-1: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 11-2: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), January'2021
  • Figure 11-3: Lumoxiti - Number of Dose Required in Single Treatment Cycle & Full Treatment, January'2021
  • Figure 11-4: Lumoxiti - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2021
  • Figure 13-1: Global - Number of Cancer Biological Toxins Related Clinical Trials by Phase, January'2021
  • Figure 13-2: Global - Cancer Biological Toxins Related Clinical Trials by Phase (%), January'2021
  • Figure 13-3: Global - Number of Cancer Biological Toxins Related Clinical Trials by Status, January'2021
  • Figure 13-4: Global - Cancer Biological Toxins Related Clinical Trials by Status (%), January'2021
  • Figure 13-5: Global - Number of Cancer Biological Toxins Related Clinical Trials by Indication, January'2021
  • Figure 13-6: Global - Cancer Biological Toxins Related Clinical Trials by Indication (%), January'2021
  • Figure 13-7: Global - Number of Cancer Biological Toxins Related Clinical Trials by Region, January'2021
  • Figure 13-8: Global - Number of Cancer Biological Toxins Related Phase I Clinical Trials by Region, January'2021
  • Figure 13-9: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 13-10: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 16-1: Drivers for the Growth of Cancer Biological Toxin Market
  • Figure 17-1: Global - Cancer Biological Toxins Expected Market Opportunity (US$ Million), 2021 -2026
  • Figure 17-2: Parameters Driving the Future Insight for Cancer Biological Toxin Market
目次

"Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
  • Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
  • Biological Toxins Drug Insight by Cancer
  • Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
  • Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a form of novel technology facility resulted from the translational research conducted at different research centers. The therapy developed and re-defined by hundreds of researchers in the past few years is witnessed to facilitate promising cancer targets in its preclinical as well as clinical research. The comprehensive outlook for the market appears to the positive, in terms of sustainable results achieved and its wide range applications to alter the future cancer therapeutics landscape.

While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable. The market since its emergence has remained ahead with respect to the overall survival rate it is delivering as well as solving the entire healthcare problems related with cancer development and progression. Several drug makers in today's world are getting involved in boosting the value chain of the market by delivering conventional thinking and re-defining the entire role of their research and development sector for the market expansion.

The market since its arrival in the cancer therapeutics market at global level has remained successful in reconfiguring today's cancer challenges by causing a shift from only being a therapy to becoming one of the standard healthcare regimens for millions of patients. All this is inclining the market towards poised growth, where in the next few years, the market will observe an influx in the market size by huge percentage. The several highlights of the market are also projecting increase in demand of the drug products available under it as the disease lifestyle is becoming more prevalent, thus making the researchers unlock more hidden potential of the therapy for different cancer patient types.

Traditionally, the cancer biological toxin market is prone to deliver and provide value in terms of complete eradication of the cancer cells by performing splendid research and development activities. But an important reason that has led to substantial rise in the clinical and research activities related with cancer is the overhaul that the other available cancer therapies had created for the past many decades. This resulted in the foundational shift in the entire cancer therapeutics industry and thus, the emergence of therapy that involves toxins isolated from prokaryotes for killing the cancer cells. To date, researchers have been successful in isolating and studying the expression of biological toxins from different organisms for killing cancer cells but one most studied bacterium for the therapy is Clostridium botulinum.

The respective bacterium and several others have promised highest returns for the cancer patients. Also, the toxins isolated from such living organisms and their transformation into drug products have led to the representation of the therapy in top best-selling cancer therapies at global level. The market due to several ongoing processes and certain achievements of the past is expected to continue to observe strong growth, with a CAGR rate of double-digit. There are numerous parameters that are associated with the market and acting as drivers. Some of the driving forces for the market are: increase in cancer cases, increase in cancer mortality rate, increase in awareness about the applications of cancer biological toxins and high failure rate of other therapies available in the market.

The unexpected status of the cancer biological toxin market has also resulted in challenging the business model of other therapies. The market's growing research spending amount and involvement of leading players of the pharmaceutical industry are also causing a robust demonstration of the applications and wide healthcare opportunities associated with the market. In addition, the therapy market is being measured as a superior therapy carrying all parameters for getting classified as a standard of care rather than just a usual cancer therapy for the patients. The healthy outcomes associated with the market are also directly linking the market to hedge over the highly expensive market such as chemotherapy, immunotherapy or any other combination therapy.

Table of Contents

1. Introduction to Biological Toxins

  • 1.1 Overview
  • 1.2 Evolution of Biological Toxins as Potent Anticancer Therapeutics

2. Role of Biological Toxins in Cancer Management

3. Types of Biological Toxins for Targeting Cancer

  • 3.1 Single Chain Biological Toxins
  • 3.2 Pore Forming Toxins
  • 3.3 Anthrax Toxins

4. Impact of Growing Cancer Biological Toxin Market on Other Viable Cancer Therapies

  • 4.1 Global Impact of Cancer Biological Toxin Therapy Market on Cancer Immunotherapy Market
    • 4.1.1 Cancer Biological Toxin Therapy Vs. Immune Checkpoint Inhibitor Therapy
    • 4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    • 4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
  • 4.2 Global Impact of Cancer Biological Toxin Therapy Market on Old & Traditional Cancer Therapies
    • 4.2.1 Cancer Biological Toxin Therapy Market Vs. Chemotherapy for Cancer Patients
    • 4.2.2 Cancer Biological Toxin Therapy Market Vs. Radiation Therapy for Cancer Treatment
    • 4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

5. Biological Toxins for Brain Tumors

  • 5.1 Toxins Used for Targeting Brain Tumors
  • 5.2 Pseudomonas Exotoxin-Based Immunotoxins for Brain Tumors
    • 5.2.1 IL4-PE
    • 5.2.2 IL13-PE
    • 5.2.3 TP-38
  • 5.3 Diphtheria Toxin-Based Immunotoxins for Brain Tumor
    • 5.3.1 Tf-CRM107
    • 5.3.2 DTAT & DTAT13
  • 5.4 Antigens for Targeting Brain Tumor
    • 5.4.1 Transferrin Receptor
    • 5.4.2 Interleukin-4 Receptor
    • 5.4.3 Interleukin-13 Receptor
    • 5.4.4 Epidermal Growth Factor Receptor
    • 5.4.5 Other Antigens

6. Biological Toxins Against Hematological Tumors

  • 6.1 Role of Biological Toxins in Leukemia & Lymphoma
  • 6.2 Ongoing Research & Development

7. Biological Toxins For Targeting Solid Tumors

  • 7.1 Impact on Solid Tumor Treatment
  • 7.2 Ongoing Research & Advancements

8. Biological Toxins for Breast Cancer

  • 8.1 Application of Biological Toxins in Breast Cancer
  • 8.2 Ongoing Development

9. Biological Toxins for Lung Cancer

  • 9.1 Role & Applications
  • 9.2 Recent Research & Development

10. Biological Toxins For Other Cancers

  • 10.1 Prostate Cancer
  • 10.2 Melanoma
  • 10.3 Colorectal Cancer
  • 10.4 Gynecological Cancer
  • 10.5 Gastrointestinal Cancers

11. Global Immunotoxin Market - Availability, Dosage, Patent & Price Analysis

  • 11.1 Lumoxiti (Moxetumomab pasudotox)

12. Research & Medical Advancement for Cancer Biological Toxin Market

  • 12.1 UCLA Researchers to Minimize Cancer Side Effects by Using Protein Derived from Diazona angulata
  • 12.2 Botulinum Toxin Effective against Stomach Cancer Cells in the Patients
  • 12.3 Botulinum Toxin A to Drastically Reduce Complications After Esophageal Cancer Treatment
  • 12.4 Botulinum Toxin A against Cutaneous Leiomyomas Indicating for Better Results
  • 12.5 TR1801-ADC Characterization for the Treatment of Advanced Solid Cancer
  • 12.6 Botulinum Toxin to Increase the Effectiveness of Chemotherapy & Radiation Therapy
  • 12.7 Botulinum Toxin A Cure for Persistent Pain after Breast Cancer Surgery
  • 12.8 Newly Discovered Botulinum Toxin X to have Potential for Treating Cancer & Other Diseases

13. Cancer Biological Toxins - Clinical Trial Insight

  • 13.1 By Phase
  • 13.2 By Status
  • 13.3 By Cancer Type
  • 13.4 By Countries

14. Global Cancer Biological Toxins Clinical Pipeline By Company, Indication & Phase

  • 14.1 Research
  • 14.2 Preclinical
  • 14.3 Phase-I
  • 14.4 Phase-I/II
  • 14.5 Phase-II
  • 14.6 Phase-II/III
  • 14.7 Phase-III
  • 14.8 Preregistration
  • 14.9 Registered

15. Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

16. Global Cancer Biological Toxin Therapeutics Market Dynamics

  • 16.1 Favourable Market Parameters
  • 16.2 Market Challenges

17. Future Directions for Cancer Biological Toxin Market

18. Competitive Landscape

  • 18.1 Angimmune
  • 18.2 Eisai
  • 18.3 Molecular Template (mTEM)
  • 18.4 Astrazeneca
  • 18.5 Research Corporation Technologies
  • 18.6 Sanofi
  • 18.7 Seattle Genetics
  • 18.8 Roche
  • 18.9 Neopharma
  • 18.10 Xenova Biomedix
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.